We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

3405:TSEKuraray Co., Ltd. Analysis

Data as of 2026-05-18 - not real-time

₩57,400.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

T&L Co., Ltd. is trading below its 20‑day and 50‑day moving averages, signaling short‑term weakness despite a broader bullish trend indicated by the price staying above the 200‑day average. The RSI hovers around the midpoint, suggesting neither overbought nor oversold conditions, while the MACD histogram is negative, pointing to bearish momentum in the near term. Fundamentally, the company shows solid profitability with healthy operating and net margins, a strong return on equity, and a modest debt‑to‑equity ratio, complemented by a comfortable dividend payout and a cash pile far exceeding its debt. However, the discounted cash flow model values the stock at roughly half of its current market price, implying a significant valuation gap. The sector’s average PE is much higher than the forward PE of T&L, indicating relative cheapness on a peer basis, yet the DCF discrepancy raises concerns of overvaluation. Volume is on an upward trajectory, providing better liquidity, but the 30‑day volatility remains elevated, reflecting price swings. Overall, the stock offers an attractive dividend yield and solid fundamentals, but price appreciation may be limited unless the valuation narrows.
Investors should weigh the dividend sustainability and strong cash generation against the current premium to intrinsic value, while monitoring technical signals for any shift toward a more decisive trend.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price below short‑term moving averages
  • negative MACD histogram
  • stable dividend but limited upside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • strong operating cash flow and low leverage
  • attractive dividend yield
  • technical bullish trend above long‑term average

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • consistent profitability and ROE
  • valuation premium to DCF fair value
  • sustained dividend policy

Key Metrics & Analysis

Financial Health

Revenue Growth-28.20%
Profit Margin23.19%
P/E Ratio7.4
ROE20.44%
ROA13.99%
Debt/Equity0.16
Op. Cash Flow₩37.7B
Free Cash Flow₩10.9B
Industry P/E26.9

Technical Analysis

TrendBullish
RSI49.4
Support₩52,000.00
Resistance₩68,000.00
MA 20₩60,140.00
MA 50₩54,928.00
MA 200₩51,569.25
MACDBearish
VolumeIncreasing
Fear & Greed Index89.61

Valuation

Fair Value₩28,721.30
Target Price₩85,000.00
Upside/Downside48.08%
GradeOvervalued
TypeValue
Dividend Yield2.61%

Risk Assessment

Beta0.96
Volatility69.83%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.